Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 5/2017

01-10-2017 | Review

Evaluation of fracture risk in chronic kidney disease

Authors: Pablo Antonio Ureña Torres, Martine Cohen-Solal

Published in: Journal of Nephrology | Issue 5/2017

Login to get access

Abstract

Chronic kidney disease (CKD) is associated with mineral and bone disorders (MBD) that are now considered as a syndrome. Bone fragility and a four to tenfold increased rate of skeletal fractures are often reported in CKD patients. The evaluation of the risk of these fractures in CKD patients should explore the same risk factors identified for the general population including low body weight, menopause, personal and familial history of osteoporosis, chronic inflammatory diseases, and corticosteroid therapy. The aim of this article is to provide a critical review of the tools used for the evaluation of bone loss and the risk of fracture in CKD patients, ranging from the measurement of bone mineral density (BMD), fracture risk assessment (Frax™), quantitative computed tomography (QCT), high-resolution peripheral quantitative computed tomography (HRpQTC), to circulating biomarkers of bone metabolism including vitamin D, parathyroid hormone (PTH), bone-specific alkaline phosphatase, osteocalcin, and some collagen type 1-related molecules indicators of bone remodeling.
Literature
1.
Dhayat NA, Ackermann D, Pruijm M et al (2016) Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int 90(3):648–657CrossRefPubMed
2.
Urena-Torres P, Prie D, Keddad K et al (2014) Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol 15:71CrossRefPubMedPubMedCentral
3.
Naylor KL, McArthur E, Leslie WD et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86(4):810–818CrossRefPubMed
4.
5.
Ensrud KE, Parimi N, Fink HA et al (2014) Estimated GFR and risk of hip fracture in older men: comparison of associations using cystatin C and creatinine. Am J Kidney Dis 63(1):31–39CrossRefPubMed
6.
Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70(7):1358–1366CrossRefPubMed
7.
Tentori F, McCullough K, Kilpatrick RD et al (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85(1):166–173CrossRefPubMed
8.
Maravic M, Ostertag A, Urena P, Cohen-Solal M (2016) Dementia is a major risk factor for hip fractures in patients with chronic kidney disease. Osteoporos Int 27(4):1665–1669CrossRefPubMed
9.
Klawansky S, Komaroff E, Cavanaugh PF Jr et al (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14(7):570–576CrossRefPubMed
10.
KDIGO (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1–S130
11.
Jassal SK, von Muhlen D, Barrett-Connor E (2007) Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res 22(2):203–210CrossRefPubMedPubMedCentral
12.
13.
Ersoy FF, Passadakis SP, Tam P et al (2006) Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 24(1):79–86CrossRefPubMed
14.
Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A (2000) Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13(6):437–443PubMed
15.
Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA (2002) Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 39(4):843–849CrossRefPubMed
16.
Negri AL, Barone R, Quiroga MA et al (2004) Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int 24(2):163–168PubMed
17.
Piraino B, Chen T, Cooperstein L, Segre G, Puschett J (1988) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30(2):57–62PubMed
18.
Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T (1999) Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33(2):287–293CrossRefPubMed
19.
Elder GJ, Mackun K (2006) 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 21(11):1778–1784CrossRefPubMed
20.
Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G (2000) Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 54(3):218–226PubMed
21.
Jamal SA, Gilbert J, Gordon C, Bauer DC (2006) Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 21(4):543–548CrossRefPubMed
22.
Kaji H, Suzuki M, Yano S et al (2002) Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 22(4):325–331CrossRefPubMed
23.
Urena P, Bernard-Poenaru O, Ostertag A et al (2003) Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 18(11):2325–2331CrossRefPubMed
24.
Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S (1996) Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone 19(5):549–555CrossRefPubMed
25.
Bucur RC, Panjwani DD, Turner L, Rader T, West SL, Jamal SA (2015) Low bone mineral density and fractures in stages 3–5 CKD: an updated systematic review and meta-analysis. Osteoporos Int 26(2):449–458CrossRefPubMed
26.
Iimori S, Mori Y, Akita W et al (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients–a single-center cohort study. Nephrol Dial Transplant 27(1):345–351CrossRefPubMed
27.
Naylor KL, Garg AX, Zou G et al (2015) Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10(4):646–653CrossRefPubMedPubMedCentral
28.
West SL, Lok CE, Langsetmo L et al (2015) Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 30(5):913–919CrossRefPubMed
29.
Yenchek RH, Ix JH, Shlipak MG et al (2012) Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7(7):1130–1136CrossRefPubMedPubMedCentral
30.
Jamal SA, West SL, Nickolas TL (2014) The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int 25(1):71–76CrossRefPubMed
31.
Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26(6):1368–1376CrossRefPubMed
32.
33.
Mares J, Ohlidalova K, Opatrna S, Ferda J (2009) Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients. J Bone Miner Metab 27(2):217–223CrossRefPubMed
34.
Jamal SA, Swan VJ, Brown JP et al (2010) Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis 55(2):291–299CrossRefPubMed
35.
Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC (2014) Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol 9(7):1254–1262CrossRefPubMedPubMedCentral
36.
37.
Nickolas TL, Jamal SA (2015) Bone kidney interactions. Rev Endocr Metab Disord 16(2):157–163
38.
Hasegawa K, Hasegawa Y, Nagano A (2004) Estimation of bone mineral density and architectural parameters of the distal radius in hemodialysis patients using peripheral quantitative computed tomography. J Biomech 37(5):751–756CrossRefPubMed
39.
Bacchetta J, Boutroy S, Vilayphiou N et al (2010) Assessment of bone microarchitecture in chronic kidney disease: a comparison of 2D bone texture analysis and high-resolution peripheral quantitative computed tomography at the radius and tibia. Calcif Tissue Int 87(5):385–391CrossRefPubMed
40.
41.
Behets GJ, Spasovski G, Sterling LR et al (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87(4):846–856CrossRefPubMed
42.
Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47(1):149–156CrossRefPubMed
43.
Lertdumrongluk P, Lau WL, Park J, Rhee CM, Kovesdy CP, Kalantar-Zadeh K (2013) Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant 28(10):2535–2545CrossRefPubMedPubMedCentral
44.
Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36(6):1115–1121CrossRefPubMed
45.
Fuller DS, Pisoni RL, Bieber BA, Gillespie BW, Robinson BM (2013) The DOPPS Practice Monitor for US dialysis care: trends through December 2011. Am J Kidney Dis 61(2):342–346CrossRefPubMed
46.
Fishbane S, Hazzan AD, Jhaveri KD, Ma L, Lacson E Jr (2016) Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis. Clin J Am Soc Nephrol 11(6):1063–1072CrossRefPubMedPubMedCentral
47.
Russo CR, Taccetti G, Caneva P, Mannarino A, Maranghi P, Ricca M (1998) Volumetric bone density and geometry assessed by peripheral quantitative computed tomography in uremic patients on maintenance hemodialysis. Osteoporos Int 8(5):443–448CrossRefPubMed
48.
Lu KC, Ma WY, Yu JC, Wu CC, Chu P (2012) Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism. Clin Endocrinol (Oxf) 76(5):634–642CrossRef
49.
Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B (2007) Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18(8):2401–2407CrossRefPubMed
50.
Yajima A, Tanaka K, Tominaga Y et al (2001) Early changes of bone histology and circulating markers of bone turnover after parathyroidectomy in hemodialysis patients with severe hyperparathyroidism. Clin Nephrol 56(1):27–34PubMed
51.
Moe SM, Abdalla S, Chertow GM et al (2015) Effects of Cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26(6):1466–1475CrossRefPubMed
52.
Urena-Torres P, Metzger M, Haymann JP et al (2011) Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am J Kidney Dis 58(4):544–553CrossRefPubMed
53.
Singer RF (2013) Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin Dial 26(1):40–46CrossRefPubMed
54.
Coen G, Mantella D, Manni M et al (2005) 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68(4):1840–1848CrossRefPubMed
55.
Napoli N, Strollo R, Sprini D, Maddaloni E, Rini GB, Carmina E (2014) Serum 25-OH vitamin D in relation to bone mineral density and bone turnover. Int J Endocrinol 2014:487463PubMedPubMedCentral
56.
Aggarwal HK, Jain D, Yadav S, Kaverappa V (2013) Bone mineral density in patients with predialysis chronic kidney disease. Ren Fail 35(8):1105–1111CrossRefPubMed
57.
Ambrus C, Almasi C, Berta K et al (2011) Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol 43(2):475–482CrossRefPubMed
58.
Mucsi I, Almasi C, Deak G et al (2005) Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol 64(4):288–294CrossRefPubMed
59.
Tomida K, Hamano T, Mikami S et al (2009) Serum 25-hydroxyvitamin D as an independent determinant of 1–84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 44(4):678–683CrossRefPubMed
60.
Bischoff-Ferrari HA, Dawson-Hughes B, Whiting SJ (2011) Vitamin D supplementation and fracture risk. Arch Intern Med 171(3):265 (author reply—6) CrossRefPubMed
61.
Reid IR, Gallagher DJ, Bosworth J (1986) Prophylaxis against vitamin D deficiency in the elderly by regular sunlight exposure. Age Ageing 15(1):35–40CrossRefPubMed
62.
Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60(1):139–156CrossRefPubMed
63.
Ueda M, Inaba M, Okuno S et al (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77(10):1130–1139CrossRefPubMed
64.
Ueda M, Inaba M, Okuno S et al (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40(4):802–809CrossRefPubMed
65.
66.
Hamano T, Tomida K, Mikami S et al (2009) Usefulness of bone resorption markers in hemodialysis patients. Bone 45(Suppl 1):S19–S25CrossRefPubMed
67.
Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y (2005) Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 51(12):2312–2317CrossRefPubMed
68.
Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16(5):501–509CrossRefPubMed
69.
Prie D, Beck L, Urena P, Friedlander G (2005) Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 14(4):318–324CrossRefPubMed
70.
Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D (2008) Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73(1):102–107CrossRefPubMed
71.
Wesseling-Perry K, Pereira RC, Tseng CH et al (2012) Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 7(1):146–152CrossRefPubMed
72.
Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG (2016) FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner. J Bone Miner Res 31(1):129–142CrossRefPubMed
73.
Carrillo-Lopez N, Panizo S, Alonso-Montes C et al (2016) Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 90(1):77–89CrossRefPubMed
74.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945–1953
Metadata
Title
Evaluation of fracture risk in chronic kidney disease
Authors
Pablo Antonio Ureña Torres
Martine Cohen-Solal
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2017
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-017-0398-6

Other articles of this Issue 5/2017

Journal of Nephrology 5/2017 Go to the issue

Review

Update on the role of bone biopsy in the management of patients with CKD–MBD

Review

Positioning novel biologicals in CKD-mineral and bone disorders

Editorial

Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?

Review

Circulating markers of bone turnover

Review

Osteoporosis, bone mineral density and CKD–MBD: treatment considerations

Review

Vitamin D and osteoporosis in chronic kidney disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits